Hyderabad to be global hub of Sandoz, to create 1,800 jobs

Sandoz has announced setting up of its Global Capability Centre in Hyderabad which will provide support for the company’s worldwide knowledge services

Hyderabad to be global hub of Sandoz, to create 1,800 jobs
X

HYDERABAD: Cementing Hyderabad’s leadership position in the pharma industry, Sandoz has announced setting up of its Global Capability Centre in Hyderabad which will provide support for the company’s worldwide knowledge services. The centre will initially have a workforce of 800 employees, with plans to increase to approximately 1,800 people in the near future.

The announcement was made after the leadership team of Sandoz, CEO Richard Saynor, Chief Scientific Officer Claire D’Abreau-Hayling, Head Sandoz Development Centre India Dr. Vandana Singh and Head, Novartis Corporate Centre Naveen Gullapalli, met with Telangana Minister for IT and Industries KT Rama Rao on Tuesday.

Sandoz had a development centre in Genome Valley engaged in cutting edge R&D facilities. The team also informed the Minister that they would be adding a state-of-the-art laboratory focused on automation in the genome valley facility. The Minister also presented the Hyderabad Pharma City project and highlighted the value proposition for companies like Sandoz. He invited Sandoz to consider setting up a large manufacturing centre in Hyderabad.

KTR siad, “I’m delighted that Sandoz has chosen Hyderabad to set up its global capability centre. Hyderabad boasts a top-notch business environment backed by the state, with a strong emphasis on the life sciences industry. Hyderabad is already home to Novartis and has grown into the second largest location for the company, we are looking forward to a similar patronage and association with Sandoz”.

Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, their vision is to discover new ways to improve and extend people's lives. The global portfolio of Sandoz comprises approximately 1,000 molecules, covering all major therapeutic areas, which accounted for 2019 sales of USD 9.7 billion. Their products reach more than 500 million patients globally.

Next Story

Similar Posts